Drug Type CAR-T |
Synonyms |
Target |
Action antagonists |
Mechanism EGFRvIII antagonists(Epidermal growth factor receptor variant III antagonists), Immunologic cytotoxicity, T lymphocyte replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glioblastoma | Preclinical | China | 24 Aug 2022 |